Method for treating ulcerous defects at diabetic foot syndrome
FIELD: medicine, purulent surgery.
SUBSTANCE: it is necessary to apply dressings with suspension consisting of thrombocytes-rich plasma, 10%-CaCl2 solution at equal volume and antibacterial preparation to which ulcerous microflora is sensitive. The volume of dressing for 1 dressing should be determined by the following formula: V=S×h×C, where S - the area of ulcerous defect, h - its depth, C - the coefficient. At the rate of ulcerous surface epithelization being under 25% weekly C=1.25, and at the rate being above 25% weekly C=1.0. The innovation provides the chance for individual dosing autogenous tissue growth factors and matched efficient antibacterial preparations and, thus, accelerated phase II of wound process and shortened terms of epithelization of ulcerous defects in the present category of patients.
EFFECT: higher efficiency of therapy.
The invention relates to medicine, namely to purulent surgery, and can be used for the treatment of nonhealing ulcers in the diabetic foot syndrome.
Diabetic foot syndrome is one of the serious complications of diabetes. From 40 to 70% of all nontraumatic amputations in the world is produced in patients with diabetes mellitus . According to the center "Diabetic foot" International Program "Diabetes" in 19.4% of cases amputation is preceded by a nonhealing foot ulcer. The average duration of treatment in these patients is 4 months, and 10% of patients - more than a year . This is due to the fact that the course of wound healing in patients with diabetes mellitus has its own characteristics, namely low rate of epithelialization of the ulcer surface, the tendency to generalization of infection, negative impact on the reparative processes of chronic renal failure. From literature data it is known the role of growth factors and cytokines in the treatment of chronic ulcers and nonhealing wounds, also points to the significant reduction in the level of growth factors in patients with diabetes .
A new trend in surgery is the use of platelet-rich plasma to accelerate the process of regeneration. Platelet-rich plasma is an autologous is i.i.d. source of growth factors, which is obtained by separation of whole blood by density gradient. Platelet-rich plasma contains high concentrations of platelet-derived growth factor and transferowy growth factor .
A study of patent and scientific and medical literature has identified the following methods that are used to treat ulcers in the diabetic foot syndrome.
There is a method of treatment of diabetic foot syndrome  by applying ozone. The method involves intraarterial introduction of antiseptic - ozonated saline solution in combination with the local effects of ozonized physiological solution in two stages. At the first stage removes necrotic tissue stream with the output pressure of 80 atmospheres. In the second stage infiltrate the fabric of the jet with the outlet pressure of 150 atmospheres. In the particular case intraarterially ozonated saline solution is administered in therapeutic dose up to 5 times per day course of treatment up to 15 days.
The disadvantages of the method are that it does not provide additional infusion of autologous factors that accelerate epithelialization of the ulcer. Intraarterial injection of ozonized physiological solution increases the number of medical invasions and increases the number of "entrance gate" infection in the blood system on f is not severe immunosuppression. Infiltration of the tissues of ozonized physiological solution under high pressure will cause mechanical damage to the latter, which will adversely affect the course of the wound process and can contribute to the generalization of inflammation.
There is a method of treatment of diabetic angiopathies of the lower extremities , which includes the improvement of microcirculation impact on patient centrifugal forces in the direction of the head of the lower limb. The speed of rotation of the centrifuge 36-42 rpm Mode of treatment is determined by the achievement and maintenance of gravitational hyperemia of the lower extremities, and increased regional blood flow, as evidenced by the increase factor photoplethysmogram feet, measured according to the formula.
Similar cannot be used to treat infections of the soft tissues of the foot. Similar is contraindicated for patients with diseases involving narusheniami cerebral and coronary blood flow, as well as conditions involving changes in the physical state of the blood and a tendency to thrombosis. For the application of the method requires special equipment, which greatly limits its clinical use.
There is a method of treatment of destructive forms of diabetic foot syndrome , used for the local treatment of patients who aharmim diabetes with purulent-necrotic complications of the foot and the high resistance of microorganisms to antibiotics. The method consists in the use of the drug, reducing the resistance of microbes to antibiotics, which is used as a 1% solution of hydrochloric acid, which impose in the form of a wet bandage on the wound surface pre-coated with an antibiotic. Ligation repeat daily until fresh granulation.
The disadvantages of the method are related to the fact that the application of 1% solution of hydrochloric acid on the purulent wound can only lengthen and strengthen" phase hydration of the wound healing process, not exerting a positive influence on the regeneration of tissues exposed to purulent inflammation, due to the effect of a 1% solution of hydrochloric acid, "reducing the resistance of microbes to antibiotics".
There is a method of treatment of trophic ulcers on the background of diabetic foot syndrome, in which the femoral artery of the affected limb injected autolymphocyte treated Glutoxim 20 mg for 45 min Autolymphocyte get on plasmasphere blood cells AS-TEC 204 firms "Fresenius". The procedure is performed twice with an interval of 48-72 h .
The disadvantages of the method are that it does not impact directly on the affected soft tissue, the method does not use individually, taking into account the sensitivity of selected antibacterial agents.
There is a method of surgical treatment of chronic is unspecified lower limb ischemia, as well as diabetic foot syndrome, in which one you have several different angles trepanation channels, blind with extra set of conductors used to carry out subsequent effects on the bone marrow of low-intensity laser radiation at the time of its aggregate impact on the bone marrow in a single session from 5.0 to 30 minutes and intraosseous administration of drugs, as the outer physical therapy effects using the effects of ultrasound with a frequency of 880 kHz intensity of 0.4 W/cm for 5-6 minutes per session, carried out in the projection zones are made canals and along the great vessels, and the number of sessions of exposure to ultrasound and low level laser radiation is at least five that provides the blood supply to the limb .
The disadvantages of the method due to the lack of techniques to accelerate epithelialization of the ulcer, to suppress infectious inflammation, in addition, the mechanical stresses on the bone of patients with diabetes, can lead to the development of complications such as deep intermuscular abscess and osteomyelitis.
It is known tool that improves peripheral circulation, which it is used for the treatment of diabetic foot syndrome. The invention lies in the fact that the suggested means to improve the peripheral blood circulation local action contains both nitroglycerin and aminophylline in again the type for local action. The tool may be made in the form of an emulsion, gel, ointment .
The method has the following disadvantages - it does not impact on the wound surface autogenous tissue growth factors and antibiotics.
There is a method of treatment of purulent wounds by exposure to jet antiseptic under pressure, characterized in that the wound affect stream antiseptic with an output pressure of 40-50 ATM from a distance of 8-10 cm from its surface, then fine stream of ozonized solution with an output pressure of 70-90 ATM from a distance of 2-3 cm from the surface of the wound with exposure 4-5/cm2the area of the wound daily until the appearance of granules, after which irrigate granulation fine stream of ozonized solution at a pressure of 10-15 ATM daily until complete epithelialization of wounds .
The disadvantages of the method are that it does not provide additional infusion of autologous factors that accelerate epithelialization of the ulcer. Irrigation of the tissues of ozonized physiological solution under high pressure can lead to mechanical damage that will adversely affect those who drop wound healing and may contribute to the generalization of inflammation.
The prototype of the present invention as the most similar set of features of the claimed method the chosen method of treating ulcers in the diabetic foot syndrome , including the use of the napkin "Al" with different active substances in a certain sequence.
The disadvantage of this method is the lack of napkins "Al" autogenous tissue growth factors that accelerate the II phase of wound healing and epithelization. In addition, when using wipes "Al" it is impossible to make an individual selection of antibacterial drugs.
The task of the invention is to accelerate the second phase of wound process, the holding of local antibiotic therapy in combination with the stimulation of epithelialization of the ulcer surface.
This object is achieved in that when the dressings used suspension consisting of platelet-rich autoplasma antibiotic to which sensitive microflora ulcers, and CaCl2, the volume of sediment is determined by a formula that takes into account the size of the ulcers and the rate of epithelialization.
The method is as follows. Collect 200-300 ml of autologous blood through a Central venous catheter with a speed of 50 ml/min in a centrifuge that rotates at a speed of 5600 rpm During blood sampling for PR is to prevent clotting automatically add preservative (nitroglycerin) in a ratio of 1 ml of preservative 5 ml of blood. In the centrifuge the blood is divided into three factions: the red blood cells, platelet-rich plasma and depleted platelet plasma. First separate depleted platelet plasma (about 150 ml). Once separated depleted platelet plasma, the rotation speed of the centrifuge is reduced to 2400 rpm for more accurate separation of platelet-rich plasma and erythrocytes. Then separate the platelet-rich plasma (about 70 ml), the latter is separated erythrocytes (about 180 ml). Plasma is straw-yellow in color and is placed in the package (container) for storing blood products. Stored in the refrigerator. Before applying 10 ml of platelet-rich plasma fill the syringe, then add 10 ml of 10% solution of calcium chloride (CaCl2). The syringe shake before coagulation, and then its contents are mixed with the antibiotic (which has a sensitivity of microorganisms).
The volume of sediment with biologically active substances necessary for one ligation, calculated by the formula: V=SxhxK, where S is the area of the ulcer, h is the depth of the ulcer, the K - factor.
When the rate of epithelialization of the ulcer surface less than 25% in week K=1,25, when the rate of epithelialization of the ulcer surface more than 25% per week To a=1.
Suspension is applied to the surface slowly granulating ulcers. Ligation is performed 2 times in the night. Spend antibacterial therapy taking into account the sensitivity of microflora, symptomatic therapy of diabetes mellitus.
The method was tested in 14 patients in the surgical Department MLPOS GB No. 7 of Rostov-on-don.
A specific example of the method.
Patient D., 64 years old, was admitted to the surgical Department 14.06.2005 year with complaints about the presence of extensive long-term unhealed ulcers on the plantar surface of the right foot. For 15 years has diabetes type 2, severe, 5 months. back on the plantar surface of the right foot was formed, the ulcer gradually increasing in size. Were outpatients with minor effect appeared sluggish granulations. Admission: General condition of the patient moderate. The pulse rate of 72 per minute. AD=130/75 mm Hg At examination revealed neuro-ischemic form of diabetic foot syndrome with a prevalence of neuropathy, 3 tbsp. At primary inspection: on the plantar surface of the right foot in the area of the 1st metatarsus-galanopoulou articulation has ulcer 3×4×1.2 cm, the bottom is made sluggish by granulation tissue with areas of overlap fibrin. The edges of the ulcer - "saped"presented by hyperkeratosis. Radiography: expressed phenomena of osteoporosis metatarsal head 1 and the main phalanx 1 finger. When taking a deep biopsy revealed Staphylococcus aureus, Chu is responsive to Ceftriaxone. Immunological studies of tissue ulcers installed a sharp decline in T-cell and epidermal growth factors.
Diagnosed with diabetes mellitus type 2, moderate, neuro-ischemic form (with the prevalence of neuropathy) of the diabetic foot, 2nd degree, trophic ulcer of the right foot. Assigned glucosaminidase and neurotropic therapy.
Preparation of suspension held in accordance with the developed method.
During the first ligation isikli ulcer edge, represented by hyperkeratosis. On the ulcer surface was covered 18 ml suspension of platelet-rich plasma and Ceftriaxone. Ligation was performed two times a day. By the 5th day appeared marginal epithelization. The amount of the mixture applied with dressings was calculated by the presented formula. 23 days of ulcers completely epithelials. In the same period revealed normalization of epidermal growth factor. At the control examination after 6 months. the plantar surface of the right foot with areas of hyperkeratosis, ulcer not.
Compared with the prototype of the proposed method for the treatment of ulcers in the diabetic foot syndrome shortens the period of epithelialization of the ulcer surface through the use of autogenous tissue growth factors that accelerate the II phase of wound healing and epithelization. When using botanova method is effective individual selection of antibacterial drugs.
1. Dedov I.I. coauthors. Diabetic foot, M. 2005
2. Guriev YA, with co-authors. Diabetic foot. Is it possible effective prevention?. Breast cancer, Volume 9, No. 24, 2001
3. Myskina N.A., Tokmakova, A., Antsiferov could BE the Process of reparation of venous ulcers in patients with diabetes mellitus" problems of endocrinology, 2004 t, No. 2, P.34-38.
4. Oral surg Oral med Oral pathol Radiol endod 1998, 85 P. 638-646.
5. RF patent 2154484 C2 from 2000.08.20.
6. RF patent 2227005 C2 from 2004.04.20.
7. RF patent 2184551 C2 from 2002.07.10.
8. RF patent 2228204 C2 from 2004.05.10.
9. RF patent 2228715 C1 from 2004.05.20.
10. RF patent 2246934 C2 from 2005.02.27.
11. RF patent 2068263 C1 from 1996.10.27.
12. RF patent 2178310 C1 from 2002.01.20.
A method of treating ulcers in the diabetic foot syndrome by dressings with active substances, characterized in that the active substances used suspension consisting of platelet-rich plasma, 10%-aqueous solution of CaCL2in equal volume and antibacterial drug to which sensitive microflora ulcers, the volume of sediment for one ligation calculated according to the formula V=SxhxK, where S is the area of the ulcer, h is its depth, K - factor, and at the rate of epithelialization of the ulcer surface less than 25% in week K=1,25, and at speeds of over 25% per week K=1,0.
FIELD: organic chemistry, medicine, neurology, pharmacy.
SUBSTANCE: invention relates to novel hydrogenated pyrrolo[4,3-b]indoles of the general formula (1): , their racemates, optical isomers, geometric isomers, pharmaceutically acceptable salts and/or hydrates that can be used, for example, in treatment and prophylaxis of different neurodegenerative diseases, such as Alzheimer's syndrome. In the general formula (1): a dotted line with accompanying unbroken line represents ordinary or double bond; R1 and R2 represent independently of one another substitutes of amino group chosen from hydrogen atom, possibly substituted (C1-C6)-alkyl substituted possibly with aryl, possibly substituted phenyl, possibly substituted carbonylamino or thiocarbonylamino group, substituted acyl, possibly substituted aryl sulfonate wherein substituted in indicated R1 and R2 are chosen from (C1-C6)-alkyl, halogen atoms, nitro, carboxy, alkoxy group, aryl; R1 n represents one or some similar or different substituted of cyclic system chosen from hydrogen atom, alkyl, aryl, cyano group, halogen atom, 5-6-membered nitrogen-containing heteroaryl. Also, invention relates to methods for synthesis of these compounds, pharmaceutical compositions and their using, and to using compounds in libraries with their using.
EFFECT: valuable medicinal properties of compounds and pharmaceutical compositions, improved methods of synthesis.
20 cl, 2 tbl, 12 ex
SUBSTANCE: single-layer coating is film or gel produced from rubber latex taken in the amount of 25-98% by mass and at least one water-soluble vegetable origin polysaccharide treated with ethyl alcohol, taken in the amount of 2-75% by mass. Coating material is produced by mixing rubber latex and aqueous solution of vegetable polysaccharide treated with ethyl alcohol during 5-50 min. The obtained mass is distributed over flat surface and dried to gel or film state.
EFFECT: improved adhesive properties; easily detachable from wound surface with its epithelialization in progress; applicability for transferring skin fibroblasts to wound surface or culturing thereof.
14 cl, 2 tbl
FIELD: medicine, combustiology.
SUBSTANCE: the present innovation deals with treating vast burn wounds of IIIa degree. It is necessary to carry out wound toilet (scrubbing up, trimming and washing procedures). Then wound should be covered with a biological bandage that contains cultivated live human allogenic fibroblasts. Moreover, biological bandage should be applied on the 1st-2nd d after trauma happened. On removing the bandage one should cover the developed neoepithelium with liquid polymeric polysiloxane-polycarbonate film as aerosol. The innovation shortens the terms of therapy without development of hypertrophic cicatrix and protects epithelium under development against drying and mechanic lesions.
EFFECT: higher efficiency of therapy.
1 cl, 7 dwg, 3 ex
SUBSTANCE: it is necessary to carry out complex medicinal therapy including specific antiviral preparations, group B-vitamins, immunocorrectors, injection of antiherpetic vaccine, and, also local therapy with derinate. Additionally, since the 1st d of exacerbation it is important to inject flosteron once i/m at 1.0 ml, cefotaxym i/m twice daily per 1.0 mg for 10 d. Immunomodulator halavit on the 1st d should be prescribed i/m at the dosage of 200 mg, and then for the next 15 d - twice daily per 100 mg i/m. Diazepam for 1 mo should be injected per 5.0 mg 4 times daily, and then per 2.5 mg 4 times daily for 1 mo, as well. One should daily inject atarax per 100 mg nocturnally for 1 mo and ketorol internally per 10 mg thrice daily for 10 d. Moreover, it is necessary to apply the composition out of 50.0 g zinc oxide, 5.0 ml ACD fraction and 25.0 g "Aciclovir" cream 4 times daily for 10 d. The innovation enables to considerably increase the efficiency of therapy due to improving the main immunological values, weakening local autoimmune reactions and, also, preventing the development of psychic disorders in such patients due to affecting viral neurotropic properties.
EFFECT: higher efficiency of therapy.
3 dwg, 1 ex
FIELD: medicine, chemical-pharmaceutical industry, pharmacy.
SUBSTANCE: invention relates to an agent used in treatment of trophic ulcer. Proposed agent comprises anhydrous lanolin as an ointment base and active substance wherein the proposed agent comprises as an active substance nutrient medium-199 or nutrient medium RPMI-1640 in the ratio of ointment base and nutrient medium from 5:1 to 1:1. Also, invention relates to a method for treatment of trophic ulcer that involves applying the agent placed on napkin on wound surface. Agent containing anhydrous lanolin and nutrient medium is applied on wound surface cleared with boric acid solution for 2-3 days, After applying the agent is replaced some times per a day, and during carrying out the treatment course used agent comprises one of the following ratio of ointment base and nutrient medium (5:1, 4:1, 3:1, 2:1, 1:1), or their combination. Treatment begins using the agent with the minimal content of nutrient medium, and in case of retention of granulation and epitheliolysis processes the ratio of lanolin to nutrient medium is changed from 5:1 to 1:1. Proposed method and agent enhance effectiveness in treatment of trophic ulcers, decrease treatment period that results to decreasing loss by disability.
EFFECT: improved method of treatment, enhanced and valuable properties of agent.
2 cl, 2 tbl, 2 ex
FIELD: medicine, chemical-pharmaceutical industry.
SUBSTANCE: invention relates to a composition used for healing wounds and a method for treatment using this composition. Proposed composition comprises the following components, g/1 kg: cyanocobalamine, 4.9-5.1; propolis oily extract, 4.9-5.1; vinylinum, 170-200; low-molecular polyvinylpyrrolidone, 18-22; dimethylsulfoxide, 50-51, and glycerol, 500-550. Method involves applying the dressing material comprising a textile napkin with a region of depot-system of medicinal preparations. Depot-system has holes and comprises cyanocobalamine, propolis oily extract, vinylinum, low-molecular polyvinylpyrrolidone, dimethylsulfoxide and glycerol. Bindings are carried out as pollution of perforative holes. Using the proposed methods promotes to rapid cleansing and healing a suppurative wound. The composition possess the more expressed antibacterial effect, it doesn't cause adverse effects in treatment and expands assortment of medicinal agent for their applying on dressing materials.
EFFECT: improved, enhanced and valuable medicinal properties of composition.
3 cl, 5 ex
FIELD: organic chemistry, chemical technology, medicine, pharmacy.
SUBSTANCE: invention relates to novel hydrogenated azepino[4,3-b]indoles of the general formula (1): , their racemates, optical isomers, geometric isomers and their pharmaceutically acceptable salts and/or hydrates. In the general formula (1) a dotted line with accompanying unbroken line represents a simple or double bond; R1 and R2 represent independently of one another substitutes of amino-group chosen from hydrogen atom, possibly substituted (C1-C8)-alkyl possibly substituted with aryl, 5-6-membered azaheterocyclyl, (C1-C8)-alkoxycarbonyl, possibly substituted phenyl, possibly substituted carbonylamino- or thiocarbonylamino-group, substituted acyl, (C1-C8)-alkylsulfonyl, possibly substituted arylsulfonyl and wherein substitutes in indicated R1 and R2 are chosen independently from (C1-C8)-alkyl, halogen atoms, nitro-, carboxy-, alkoxy-group, aryl; Ri n represents one or some similar or different substitutes of cyclic system chosen from hydrogen atom, (C1-C8)-alkyl, (C6-C10)-aryl, halogen atom, 5-6-membered azaheterocyclyl. Also, invention relates to methods for synthesis of these compounds, their using and pharmaceutical composition and libraries of compounds. Synthesized compounds possess neuroprotective, cognitive-stimulating and anti-histaminic properties and can be used in treatment of different neurological disorders, allergic and autoimmune diseases, for example, for memory improvement.
EFFECT: valuable medicinal and biological properties of compounds and pharmaceutical composition, improved method of synthesis.
25 cl, 2 tbl, 12 ex
FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to drugs as ointments used in treatment of wounds and ulcerous damages of skin tissue and mucosa envelopes. Proposed medicinal agent comprises active mixture of two medicinal substances represented by thiotrazoline and laevomycetinum taken in the ratio 4:1 or 2:1. Optimal variant of ointment containing thiotriazoline and laevomycetinum comprises 2 g of thiotriazoline and 0.5 g of laevomycetinum in 100 g of ointment. Using the proposed medicinal agent as ointment enhances its wound-healing effect significantly as compared with the known preparations.
EFFECT: enhanced effectiveness of agent.
5 tbl, 5 ex
FIELD: medicine, pharmacy.
SUBSTANCE: invention proposes a pharmaceutical composition used in treatment of burns. The composition comprises N-(β-hydroxyethyl)-4,6-dimethyldihydropyrimidon-2 (xymedone) and base-forming agents. As base-forming agents the composition comprises gel-forming agent representing biopolymer sodium salts, glycerol as a water-retaining agent taken in the amount 20 wt.-%, not less, stabilizing agent, preserving agent and distilled water. In addition to xymedone variants of the composition can comprise silver nitrate or silver nitrate and sodium sulfacyl, or laevomycetinum and succinic acid as an active substance. Tests showed high effectiveness of the proposed pharmaceutical composition satisfying all medico-biological requirements imposed to design of modern medicinal agents used in treatment of burns and wounds. Proposed pharmaceutical composition can be used as an agent showing highly effective regenerating, wound-healing and improving microcirculation properties in treatment of infected burned wound.
EFFECT: valuable medicinal properties of pharmaceutical composition.
9 cl, 2 tbl, 16 ex
FIELD: chemical and pharmaceutical industry, in particular agents for treatment of skin and mucous inflammatory diseases, trophic ulcer, bed sores.
SUBSTANCE: claimed agent sea-buckthorn oil, thuja oil, calendula tincture, Kalanchoe juice, oily extracts from onion and garlic, aerosyl, emulsifier T2 in specific ratio.
EFFECT: liniment with phytocomplex having increased anti-combustion, wound-healing and anti-inflammatory action.
5 tbl, 4 ex
FIELD: medicine, ophthalmology, pharmacy.
SUBSTANCE: invention proposes a pharmaceutical composition used in treatment of cornea injuries that comprises, mas.p.p.: sodium deoxyribonucleate, 14-15; sodium chloride, 0.8-0.9; lyophilized blood plasma, 74-75, and distilled water, the balance. Components are mixed in aseptic conditions and packaged. Invention provides anti-inflammatory, antiviral, antibacterial, reparative and regenerative effect, decreasing treatment period and declining post-operative complications.
EFFECT: improved, enhanced and valuable medicinal properties of pharmaceutical composition.
2 tbl, 5 ex
FIELD: medicine, pharmaceutical industry.
SUBSTANCE: invention proposes a method for making tablets of alpha-fetoprotein preparation. Method involves mixing alpha-fetoprotein with a stabilizing agent, addition of a filling agent consisting of microcrystalline cellulose and potato starch or lactose, coating the prepared mixture by envelope consisting of acetylphthalylcellulose in the following ratio of components, weight%: alpha-fetoprotein, 0.01-0.03; stabilizing agent, 8.57-14,28; microcrystalline cellulose, 40-45.7; potato starch or lactose, 40-45.7, and acetylphthalylcellulose, 1.14-2.85. Rheopolyglucin is used as a stabilizing agent, and alpha-fetoprotein is obtained from abortive, cord or placental blood by separation of inert proteins from blood by centrifugation, fractionation of supernatant with ammonium sulfate or sodium sulfate, or ethyl alcohol for 1 h, repeated centrifugation of solution, carrying out the first chromatography treatment of supernatant on an affinity sorbent using Sepharose CL-4B, elution of alpha-fetoprotein with 0.1 M glycine-HCl buffer solution at pH 2.5 up to obtaining zero values of optical density at wavelength 280 nm, and the following chromatography treatment on an affinity sorbent using Sepharose CL-4B containing immobilized antibodies against human IgG and dialysis of alpha-fetoprotein solution against 0.15 mole/l of sodium chloride solution. The end product is diluted with rheopolyglucin up to the concentration alpha-fetoprotein 0.9 mg/ml and that of dextran 10 mg/ml. Invention provides increasing yield of alpha-fetoprotein and maximal purity of the end product, increasing stability of alpha-fetoprotein in storage, expanding region of its using and design of preparation of prolonged effect.
EFFECT: improved preparing method.
FIELD: medicine, urology.
SUBSTANCE: it is necessary to introduce autofibronectin under ureteric mucosa at the distance of about 4-5 mm being below its foramen in avascular area, at 5-6-7 endoscopic hours at the dosage of 5-10 ml till complete closing the mouth at the top of the tubercle developed. The innovation provides efficient removal of cystoureteric reflux, accelerates activation of fibroblasts and mobilization of collagen in area of fibronectin injection and prevents the manifestation of local inflammatory and general allergic reactions.
EFFECT: higher efficiency.
FIELD: medicine, in particular balneology and physical therapy.
SUBSTANCE: claimed additive contains dihydroquercetin or mixture of dihydroquercetin and milky whey in ratio from 2:1 to 1:2 as biologically active additive for balneological bath agent. Dalneological bath agent includes base, osmolytically active components such as glycerol and inorganic salts, as well as biologically active additive of plant and/or animal origin, wherein osmolytic activity is 7700-11000 mOsm/l. As biologically active additive of plant and/or animal origin it contains dihydroquercetin or mixture of dihydroquercetin and milky whey in ratio from 2:1 to 1:2 and as the base it contains water and/or concentrated milk in the next component ratio (mass %): glycerol 25.0-30.0; inorganic salts 10.0-15.0; dihydroquercetin or mixture of dihydroquercetin and milky whey 0.2-1.0; and balance: water and/or concentrated milk up to 100 %.
EFFECT: new effective additive for balneological bath agent.
5 cl, 9 ex
FIELD: medicine, oncology.
SUBSTANCE: the present innovation deals with surgical therapy and chemotherapy. Moreover, in pre-surgical period it is necessary to sample 200 ml blood in such patients, due to centrifuging blood should be divided into plasma, leukomass and thromboerythromass. One should add leukovorin into the vial with leukomass at the dosage of 500 mg/sq. m to incubate in a CO2-incubator for 24 h and fluorouracil into the vial with thromboerythromass at the dosage of 1000 mg/sq. m to incubate for 30 min. Plasma should be frozen. In the course of the operation it is important to introduce intravenously by drops the content of the vial with thromboerythromass. On the next day the incubated leukomass with leukovorin should be injected for a patient intravenously by drops. Then, in post-surgical period on the 12th-14th d defrosted plasma should be incubated with fluorouracil at the dosage of 1000 mg/sq. m and metotrexate at the dosage of 25 mg/sq. m to be intravenously injected by drops. The innovation enables to decrease the frequency of relapses and metastases, decrease toxicity of anti-tumor preparations and prolong life period and improve quality of life in such patients.
EFFECT: higher efficiency of therapy.
SUBSTANCE: method involves taken patient blood in preoperative period in the amount of 200 ml. Plasma is separated from the blood by centrifuging. 40 ml of autoplasma and chemopreparation are introduced into the first flask. The remaining blood corpuscles, plasma and chemopreparation are enclosed in the second flask. The flasks are separately incubated for 40 min at 37°C. Then, operation is executed by subserously introducing autoplasma incubated with chemopreparation from the first flask along the tumor periphery before mobilizing large intestine. Intravenous drip-feed infusion of autoblood incubated with chemopreparation from the second
flask is concurrently carried out into peripheral vein.
EFFECT: enhanced effectiveness in preventing local relapses and metastases occurrence in remote period.
FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to using blood plasma or serum as an agent for treatment of wounds and to a pharmaceutical composition used in treatment of wounds and comprising blood plasma or serum, and to a method for treatment of wounds by applying indicated composition on wound site for normalization of tissue medium around the wound site. Pharmaceutical composition for treatment of wounds comprises pharmaceutically effective amount of blood plasma and serum as an active agent with pH value in the range from 3.5 to 6.5. Invention allows using the composition for recovery, substitution, relieve, acceleration, assistance to healing and/or cure of any damaged or traumatized tissue. Also, invention relates to preparing the amount of such composition providing normalization of different activating cells of substance and pathological cells around the wound site and promotes to the wound healing.
EFFECT: improved and valuable medicinal properties of composition.
12 cl, 9 dwg, 15 ex
SUBSTANCE: method involves carrying out patient premedication with Phenozepam tablets at a dose of 0.0005-0.001 g, Sibazon intramuscularly introduced at a dose of 10 mg 30 min before operation on the eve and in the morning at operation day and Dimedrol at a dose of 10 mg. Then the patient is placed on operational table on mattress heated to temperature of 37-39°C and connected to monitor. The central vein is punctured and catheterized and preoperative patient infusion preparation is started by intravenously dropping 500 ml of crystalloid solutions heated to temperature of 37-42°C like Ringer solution or Acesol, or Trisol, or Lactasol, and the same quantity of colloid solutions HES 6% or HES 10%. Then epidural space is punctured at Th7-L1 level with subsequent catheterization following so that with catheter top being arranged at Th5-Th11 level. 4 ml of 0.5% Bupivacaine hydrochloride solution test-dose is epidurally introduced in bolus mode into the epidural space with its action being estimated. Then anesthetic is fractionally introduced in 4-5 ml large portions under arterial blood pressure and pulse control with the total amount reaching 15-20 ml with earlier entered test-dose quantity being taken in account. Oxygen inhalation is carried out through narcosis apparatus mask at a rate of 5-8 l/min on the background of independent patient breathing. Then intravenous bolus 0.1% atropine injection is introduced at a dose of 0.005 mg/kg. Anesthesia induction of 2% sodium thiopental solution is carried out at a dose of 4-5 mg/kg, and also 0.005% Phentanyl solution at a dose of 0.0025-0.0035 mg/kg as intravenous bolus injection into the central vein. Trachea intubation is carried out on the precurarization background by introducing Arduan at a dose of 1-2 mg or Esmeran at a dose of 10-20 mg. The patient is transferred to artificial lung ventilation on the background of a muscular relaxation by introducing 2% Ditiline solution at a dose of 1.5-2 mg/kg, and body temperature control gauge is arranged in the middle one-third of patient esophagus. Anesthesia is supported at all stages of operation under artificial lung ventilation conditions by carrying out inhalation with nitrous oxide and oxygen mixture with their proportion being from 2:1 up to 3:1 using flow-reversing respiratory contour having respiratory ventilation volume of 7-8 ml/kg and minute ventilation of 100-120 ml/kg. 0.5% Bupivacaine hydrochloride solution is also introduced into the epidural space every 120-150 min at a dose of 3-5 ml, Arduan is intravenously introduced every 40-60 min at a dose of 2-4 mg or Esmeron every 25-35 min at a dose of 10-20 mg. Intravenous dropping infusion of crystalloid solutions heated to temperature of 37-42°C is carried out at a rate of 10-20 ml/kg/h at neoplasm removal stage. 500 ml of colloid solutions heated to temperature of 37-42°C or 400 ml of 20% albumin solution heated to temperature of 36-37°C is intravenously introduced 25-35 min prior to the beginning of chemotherapy. Transfusion of 400-450 ml of fresh frozen blood heated to temperature of 36-37°C is carried out. The warming up mattress is switched off at chemotherapy preparation stage. Patient head occipital part and main cervical blood vessel passage area is compulsorily cooled with ice packages at the beginning of chemotherapy stage, with intravenous heated crystalloid and colloid solutions, albumin and blood plasma introduction being simultaneously terminated and crystalloid solutions introduction at room temperature being continued with patient body temperature controlled not to be above 38.5°C according to esophageal gauge indications. Sodium bicarbonate and electrolytes are intravenously introduced in planned amount after having finished the chemotherapy treatment. Anesthesia is stopped at operation finish stage by stopping introducing the preparations into the epidural space and intravenously introducing relaxants, continuing artificial lung ventilation using oxygen and air mixture with FiO2 equal 0.4-0.6.
EFFECT: maximum nociceptive pulsation blockade from surgical intervention zone; patient body temperature supported at the level of 36-37°C; prevented brain hyperthermia.
FIELD: surgery, traumatology, orthopedics.
SUBSTANCE: method of preparing platelet-rich blood autoplasma for regeneration of cortical bone consists in adding it to autogenous stabilizer blood, centrifugation, adding pre-coagulant containing 10% CaCl2 solution, and a blood coagulation factor. Centrifugation is conducted at ambient temperature for 5-8 h at a rate of 1000-2300 rpm and than 5000 units of prothrombin (blood coagulation factor II) is added.
EFFECT: increased productivity of platelet-rich blood autoplasma preparation and reduced expenses owing to exclusion of expensive equipment.
FIELD: medicine, oncology.
SUBSTANCE: the present innovation deals with treating patients in case of skin melanoma stage III. For this purpose blood plasma should be incubated with the following chemopreparations: cisplatin 30 mg, metotrexate 5 mg, cyclophosphan 600 mg in a thermostat at 37°C for 30 min and in pre-surgical period it is necessary to inject it for a patient into subcutaneous fatty fiber due to paracenteses from 4 sides under the focus of malignant growth. During the same day it is important to star gamma-therapy at the dosage of 2.4 Gy daily for 5 d, then comes 1-d-long interval and the same order of procedures should be continued twice more. In 2 d one should carry out operation in the volume of wide dissecting the primary focus at regional lymphadenectomy. In 2 wk after operation - with the same preparations and at the same dosages 5 times every other week. During the next 2 yr it is necessary to carry out analogous adjuvant autohemochemotherapy once/3 mo. Application of the complex therapy suggested enables to achieve higher percentage of tumor regression, increase duration and improve quality of life.
EFFECT: higher efficiency of therapy.
SUBSTANCE: invention relates to biomaterials and can be used in plastic surgery and stomatology in conservative treatment. Proposed material based on calcium inorganic phosphates comprises additionally calcium carbonate wherein it comprises chlorapatite, calcium and iron phosphate hydrate, calcium - iron phosphate and calcium hydrogen phosphate as calcium inorganic phosphates, and these components are taken in the definite ratio. The more ratio Fe/Ca is 0.02-0.06, and dispersed composition of the main fraction is in the range 5-40 mcm. Proposed material for medicinal using is biocompatible with living body tissues completely, it possesses transdermal activity, analgesic effect and ability for repairing and strengthening osseous tissues, and to relieve and strength dental enamel in stomatology.
EFFECT: valuable medicinal properties of material.
3 cl, 3 dwg